Life Sciences Archive » May, 2012

Life Sciences - May, 2012

259 articles

• Aerospace Deal Crucial To FCC OK For Wireless Medical Tech
• St. Jude Pumps Out $4M To End Heart Implant FCA Suit
• Q&A With Birch Stewart's MaryAnne Armstrong
• GSK Says La. Can't Use Outside Attys In $12B Avandia Suit
• Pfizer, Teva Reach Licensing Deal For Generic Zyvox
• SEC Sues Unico, Advanced Cell Over Alleged Stock Scheme
• AstraZeneca To Settle Toprol-XL Antitrust Action
• Lawmakers Brawl Over Bill To Repeal ACA Medical Device Tax
• Human Genome's Poison Pill Survives As GSK Eyes Coup
• AstraZeneca V. EC — The Advocate General's Opinion
• Barr Urges Calif. High Court To Heed Feds On Pay-For-Delay
• GSK Can't Escape Classen's Patent Infringement Suit
• House Handily Approves Sprawling FDA Reform Bill
• Pfizer Off Hook In Prempro Breast Cancer Case
• Shire Looks To Quash Mylan's Generic Colitis Drug
• Olympus Quells Contract Feud With Ousted CEO
• Tekmira Seeks DQ Of McDermott For Past Patent Work
• Lawmaker Blasts NIH For Funding Doc With Glaxo Conflict
• Tried And True Summary Judgment In Failure-To-Warn Cases
• Caraco V. Novo Nordisk: Antitrust Implications
• Q&A With Fish & Richardson's Juanita Brooks
• Pronova Defeats Teva, Par In Lovaza Patent Suit
• FDA Warns J&J It Can't Slip Away From K-Y Complaints
• Justices Reject Saint-Gobain's Bid For Higher Infringement Bar
• Haynes And Boone Lures Nixon Peabody IP Pro To NY
• Mylan, Sunovion Reach Terms In Xopenex Patent Fight
• Bingham Ramps Up Tech Ranks With Ex-DLA Piper Partner
• St. Jude Loses Occlutech Heart Implant IP Row In The Hague
• Watson, Endo Settle Generic Lidoderm Patent Suit
• Human Genome's Resistance To $2.6B GSK Offer Draws Fire
• Q&A With Sutherland's Bill Warren
• National Cancer Institute Cleared In Contracting Battle
• Dewey & LeBoeuf Files For Bankruptcy
• Allergan, Others Look To Ice Apotex Monopoly Suit
• NY Grand Jury Pins Pain Pill Abuse On Drugmakers, Doctors
• Human Genome Denies Hiding Suicide Risks In Lupus Drug Case
• House Hopes To Cut FDA Bill Costs With Biosimilars Provision
• GOP House Leader Seeks June Vote On Device Tax Repeal
• Q&A With Epstein's Wendy Goldstein
• Tightening FDA Nanotech Regs On Food, Cosmetics
• Europe Clears Roche Cancer Drug After Contamination Report
• Takeda Puts Up $247M For Brazilian Drugmaker Multilab
• Study Links Calcium Products To Higher Heart Risks
• Lab Tied To Eye Infections Halts Sterile Drug Production
• DLA Piper Plucks Latham Tech M&A Ace For Silicon Valley
• FDA User Fee Bill Easily Slides Through Senate
• Combined Prior Art Nixes Joint Patent, Fed. Circ. Rules
• Astellas Sues To Block Hospira's Generic Adenoscan
• FCC Dedicates Spectrum For Wireless Medical Devices
• Broadening Enforcement Of FDA Clinical Investigator Rule
• Q&A With Blank Rome's Terry Henry
• FDA Panel Won't Back J&J's Xarelto For ACS Patients
• Senate To Vote On Pay-For-Delay, 16 Other FDA Changes
• NJ Panel Advances Bill Speeding Class Cert. Appeals
• White House Orders Gov't Agencies To Take Data Mobile
• Dexatrim Maker Says Suit Doesn't Show Harm From Carcinogen
• Q&A With Nixon Peabody's Areta Kupchyk
• Lathrop & Gage Snags 2 Abbott Labs Attys For IP Practice
• UK Teddy Bear Co. Sues J&J Unit Over Misleading Zyrtec Ad
• Clarifying Infringement Liability Under Hatch-Waxman
• J&J Unit Targets Haupt, Ranbaxy Birth Control Generics
• House Dem Pushes Bill Targeting Gray-Market Drug Sales
• Stryker Not Liable For Man's Cartilage Damage, 6th Circ. Says
• Judge Bars Mylan's Oracea Generic In Galderma IP Case
• Judge Won't Reconsider CEO Liability For J&J Recalls
• No Deal Yet On National Drug Track-And-Trace System
• US Liable For Destroyed HIV Samples, Co. Tells 7th Circ.
• Bipartisan FDA User Fee Bill Hits Snag On Senate Floor
• Q&A With Bracewell's Michael Samardzija
• An Unprecedented Settlement For FDCA Violation
• An 'Obvious' Ruling In Abilify Composition Patent Case
• FDA Seizes Drugmaker's Unapproved Topical Scar Treatment
• IP Boutique Firm Sues Unigene Over Unpaid Fees
• Best Practices For Corporate Social Responsibility
• McCarter Boosts IP Practice With AstraZeneca In-House Atty
• GOP Sens. Blast FDA Over Reviewers' Accountability
• Pfizer Hasn't Proved Rare-Disease Drug Works, FDA Staff Says
• 7th Circ. Rejects Securities Suit Over Zimmer Hip Implant
• FDA Reviewer Backs J&J's Xarelto For Heart Condition
• Senate To Consider FDA User Fee Bill Amendments
• G-8 Hits On Drug Safety, Counterfeiting For 1st Time
• J&J Customers To Appeal Benecol False Ad Ruling
• High Court Declines 2nd Petition On Patent Evidence Limits
• Q&A With Arnold & Porter's Matthew Wolf
• Bristol, Sanofi Say Plavix Marketing Suit Isn't Supported
• Adidas Loses Injunction Bid As Herbalife Logo Battle Ends
• Applying Prometheus To Myriad: Possible Outcomes
• ViroPharma Lied About Antibiotic Exclusivity, Investor Says
• Reid Wants Monday Vote To Advance FDA User Fee Bill
• Cumberland Sues To Stop Mylan's Generic Acetadote
• Nixon Peabody Nabs Davis Wright's Health Group Vice Chair
• Va. Joins $500M Medicaid Fraud Suit Against Healthpoint
• Fenwick Snags AVI BioPharma GC For Life Sciences Practice
• FDA Issues Guidance On Biotech Pharmaceutical Testing
• Struggling J&J Unit Recalls Immodium Over Package Tears
• Royal DSM Forks Over $534M For Fish Oil Extract Co.
• Warner Chilcott Challenges Watson's Generic Contraceptive
• FDA: Show Us Your ISO Audit And We May Leave You Alone
• Q&A With Gibson Dunn's Daniel Thomasch
• On 2nd Look, Fed. Circ. Jettisons Baxter Dialysis Patent
• GOP To Wage War On ACA Regardless Of High Court Ruling
• Sanofi Units Can't Get Junk Fax Class Action Thrown Out
• Human Genome Rejects GSK's $2.6B Bid With Poison Pill
• Stiefel Must Pay Sales Rep $1.5M In ERISA, Fraud Suit
• FCC Plans Spectrum Grant For Wireless Patient Monitoring
• Cetero Purchased By Creditors In $80M Stalking Horse Deal
• Allergan Sets Up NJ Base With 93K-Square-Foot Lease
• Bayer Pays $15M To Soothe Consumers In Aspirin MDL
• Q&A With Duane Morris' Vicki Norton
• White House Endorses 'Critical' FDA User Fee Legislation
• FDA To Look At Study Linking Antibiotic To Cardiac Death
• Agilent Says $2.2B Dako Buy Will Boost Life Sciences Biz
• Patent Use Codes In The Wake Of Caraco V. Novo Nordisk
• SEC Eyes Dendreon, Possibly Over Provenge Launch
• Study Says FDA Reviews New Drugs Faster Than EU, Canada
• CalPERS' $500M Tech Property Fund Eyes Data Centers, Labs
• Feds Shut Down Off-Label Bone Graft Probe, Medtronic Says
• Allergan Sues Hi-Tech To Block Generic Lash Drug Latisse
• Senate's New FDA User Fee Bill Adds Funds For Rare Diseases
• 3rd Circ. Scraps 2 Schering Off-Label Marketing Actions
• India's Piramal Pays $635M For US Health Data Co.
• Q&A With Reed Smith's Chris Healy
• FSMA's Potential Impact, Part 1: Force Majeure Clauses
• CBO Says FDA User Fee Bill Would Save $358M Over 10 Years
• Novartis Pressures Generics Makers Over Exforge ANDA
• $100M Alzheimer's Funding Plan Includes Genentech Drug Trial
• King & Spalding Nabs Health Care Duo From Baker Donelson
• In-License Agreements With Nonprofits: 5 Considerations
• Missing Link: Food, Drug Safety In Foreign Supply Chain
• European Court Adviser Backs €53M AstraZeneca Antitrust Fine
• Q&A With Akin Gump's Dianne Elderkin
• Cardinal Agrees To Shipping Ban Over Oxycodone Orders
• Roche, Helsinn Sue Dr. Reddy's Over Bid For Generic Aloxi
• Judge Thins Malpractice Suit Over Child's Motrin Case Verdict
• NRDC Pushes To Reopen FDA Suit Over Soap Chemicals
• 41 AGs Back Bill Allowing Suits Over Generic-Drug Warnings
• FDA Urges Caution For Users Of Novartis' MS Drug
• FDA Delays Deadline For Stricter Sunscreen Labeling Rules
• Q&A With King & Spalding's Ed Basile
• Takeda Calls FCA Suit Over Unsafe Drug Interactions Baseless
• The Blurring Line Between Semi And Bio
• Hospira Recalls Overfilled Hydromorphone Injections
• Biotechs Push FDA For Clear-Cut Biosimilar Labeling Rules
• FDA Quizzed On Antibiotic Use In Corn-Based Animal Feed
• Medtronic Accused Of Off-Label Marketing Kickbacks Scheme
• New House Bill Aimed At Detecting Medical Device Risks
• GSK, Valeant Dodge Sham Patent Suit Claims In Wellbutrin Row
• Resolving Life Science Collaboration Disputes
• Canadian Ruling Puts Seroquel Suits In Limbo
• Reed Smith Snags Product Liability Guru From Dechert
• Investor Seeks To Block DSM's $360M Kensey Nash Buyout
• Q&A With Frost Brown Todd's Karlyn Schnapp
• Abbott Loses Blood Test Patent Row With Epocal
• Depomed Sues Cadila, Zydus Over Generic Gralise
• FDA Bone Drug Study Offers New Pathway For Plaintiffs
• Novartis, Lilly Rebut Indian Lawmakers' Collusion Claims
• FDA Panel Backs Approval Of Drug For HIV Prevention
• Wyeth Investors Likely To Win Class Cert. In Pristiq Case
• Medical Device Co. Accused of Artificially Inflating Stock
• FDA Panel Endorses Arena's New Obesity Drug
• State Farm Wants Out Of Pfizer Trade Dress Suit
• SEC Hits Biotech Investor With Market Manipulation Suit
• Bayer, Pharmacia To Pay $4M To Settle Superfund Suits
• Spectrum, Allos Stretch Tender Offer After FTC Info Request
• BioMed REIT Lands $92M Tenant For Empty Cambridge Lab
• FDA Targets Experimental Multiple Sclerosis Treatment
• RyMed Wins Jury Trial Over ICU's Valve Patent
• Drug Tracking Talks Continue As Panel OKs FDA Fee Bill
• Q&A With Seyfarth's John Serio
• FDA Warns Against Long-Term Use Of Osteoporosis Drugs
• The Inequitable Conduct Defense — 1 Year After Therasense
• L'Oreal Loses Botox Trademark Fight In EU
• Where Rubber Hits Road: Examples Of Alternative Fees
• Suits Against Reglan Generics Can't Skirt Mensing: NJ Court
• Fed. Circ. Finds Stroke Treatment Patent Anticipated By Study
• Notable Biotech Investor Cops To Securities Fraud
• 7th Circ. Says Admin OT Exemption Covers Pharma Sales Reps
• Sens. Allege Drugmakers Financed Opioid Misinformation
• Boston Scientific Accuses St. Jude Of Stealing Sales Data
• FDA Advisory Panel Backs Pfizer Arthritis Drug
• Kirkland Nabs 4 Kaye Scholer Pharma, Life Science Attys
• GSK Bringing $2.6B Takeover Bid To Human Genome Investors
• Unison Snags Japanese Drugmaker From Fellow PE Funds
• Q&A With Covington's Mark Lynch
• FDA Wants Child-Size Radiation Doses From Medical Imagers
• What's Next In The Myriad Genetics Case?
• RAM Faces Fines For Counterfeit, Contaminated Mesh
• Gilead's Truvada May Cut HIV Infection Risk, FDA Says
• Arena Faces New FDA Worries Over Weight-Loss Drug
• Jury Sides With Coloplast In IP Row Over Bladder Device
• Subpoenas OK In Patent Re-Exams, Cordis Tells Fed. Circ.
• FDA Panel Votes Against Approving Regeneron's Gout Drug
• FDA Says Celgene's Revlimid Tied To Higher Cancer Risks
• House Panel OKs FDA User Fees Bill Despite Sticking Points
• Savient Creditors Lose Bid To Block Debt Exchange
• Morgan Lewis Atty Sanctioned For Doc Sharing In Gene IP Row
• Mission Impossible: Impossibility Preemption Post-Levine
• Q&A With Nixon Peabody's Fred Kelly
• Top Female Trial Attorney: Reed Smith's Barbara Binis
• Device Makers Seek More Exemptions From ACA Excise Tax
• Chemist Gets 18 Months For Sanofi Trade Secrets Theft
• Reed Smith Snags Product Liability Pro From Dechert
• Shook Hardy Lures Product Liability Pro From Dechert
• Sens. Seek Study On DEA Role In Emergency Drug Shortages
• Nixon Peabody Adds Ex-Davis Wright IP Atty To LA Team
• Fed. Circ. Sides With Otsuka In Abilify Patent Validity Debate
• House Drops Potential Snag From FDA User Fee Draft Bill
• Abbott To Pay $1.6B To Settle Depakote Allegations
• Implications — And Complications — Of Undoing Mensing
• Pfizer Arthritis Drug Has Safety Risks, FDA Report Says
• Q&A With Frost Brown Todd's Steven Goldstein
• FTC 'Still In The Game' On Pay-For-Delay Challenges
• Bill Aims To Hike Penalty For Unreported Drug Trial Results
• Stryker, Racing Optics Beat Medical Face Shield Patent Row
• FDA Panel To Find If Regeneron Gout Drug's Risks Too High
• CMS Delays Sunshine Act Compliance Until Jan. 1
• Gen-Probe Shareholder Aims To Block $3.7B Hologic Deal
• Law360 Names Top Female Trial Attorneys
• Alexza's Manufacturing Issues Delay FDA Approval Of Adasuve
• Ceragenix Attacks Ousted Exec's $10M SOX Complaint
• FDA's Tightening Rein Over Foreign Clinical Trials
• Q&A With Gibbons' Estelle Tsevdos
• Genzyme Irons Out FCA Suits Over Surgery Product Marketing
• Cooley Scores Latham Capital Markets Partner In SF
• Bristol-Myers Can Seek $11M More In Stolen-Drug Insurance
• Groups Fear Obama Order Sends Excessive Power Overseas
• Haemonetics To Pay $551M For Pall's Blood Business
• Genomma Abandons $834M Prestige Brands Bid
• Wilson Sonsini Swipes Kilpatrick Townsend Patent Pro
• DOD's Drug Price Controls Unfair, DC Circ. Hears
• Boost In Reporting Cut New Drug Shortages By Half, FDA Says
• Pharma Cos. Will Open Abandoned Drugs To Outside Research
• Cleary Gottlieb Leads DSM In $360M Medical Device Co. Buy
• Takeaways From Caraco V. Novo Nordisk
• Q&A With Choate's Bill Asher
• Predictive Coding — Putting The Cart Before The Horse
• DOJ Vet With Big Biz Clients Rejoins Arnold & Porter
• 1st Circ. Affirms $26M Award In Sulindac Injury Suit
• Doctors Speak Out Against FDA's Plan For More OTC Drugs
• Q&A With Robins Kaplan's Matthew McFarlane
• J&J China Enters Medical Device Market With Bioseal Buy
• Jackson Lewis Snags Merck's International Labor Chief
• Prometheus Dooms DNA Analysis Patent, Merial Claims
• Mylan Denied Invalidity In Cancer Drug IP Battle
• FDA Loosens Sterility Testing Rules For Biologics
• The Uncertain Fate Of Learned Intermediary Doctrine
• Addressing Breach Of Method-Of-Use Patents By Generics
• Ill. Appeals Court Rejects Abbott's Bid To Move Class Action
• FDA Drug Reviews Pass Muster As User Fee Deadline Looms
• Big Biz Hails Obama's Order To Align International Regs
• FDA Urged To Require Ongoing Safety Checks For Risky Drugs
• St. Jude's Device Liability May Not End With Recalls: Report
• FDA Revised Benefit-Risk Criteria — Embracing Innovation
• Hospira Blocks Sandoz's Generic Precedex
• Pfizer Settles BYU's Long-Running Celebrex Suit
• 6th Circ. Won't Overturn Fen-Phen Attys' Convictions
• Creditor Sues Savient Pharmaceuticals To Force Liquidation
• Q&A With Reed Smith's Melissa Geist
• Chattem Concealed Carcinogen In Dexatrim, Suit Says